PTGX241115P45000
- 2.70
- -0.25-8.47%
Protagonist Therapeutics Newsroom
TD Cowen Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $65
Truist Financial Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating
Truist Financial Issues a Buy Rating on Protagonist Therapeutics (PTGX)
TD Cowen Initiates Protagonist Therapeutics(PTGX.US) With Buy Rating, Announces Target Price $65
Protagonist Therapeutics Analyst Ratings
H.C. Wainwright Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $50
Analysts Offer Insights on Healthcare Companies: Walgreens Boots Alliance (WBA), Belite Bio, Inc. ADR (BLTE) and Protagonist Therapeutics (PTGX)
Truist Financial Initiates Protagonist Therapeutics(PTGX.US) With Buy Rating, Announces Target Price $60
Truist Initiates Protagonist Therapeutics at Buy With $60 Price Target
Protagonist Therapeutics Price Target Cut to $43.00/Share From $45.00 by JMP Securities
Protagonist Therapeutics Analyst Ratings
HC Wainwright & Co. Maintains Buy on Protagonist Therapeutics, Raises Price Target to $40
JMP Securities Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $43
Capital One Financial Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $48
JMP Securities Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Cuts Target Price to $43
Buy Rating Affirmed for Protagonist Therapeutics on Strong Pipeline and Strategic Partnerships
J.P. Morgan Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $48
Protagonist Therapeutics Price Target Raised to $48.00/Share From $39.00 by JP Morgan
JP Morgan Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $48
Protagonist Therapeutics Analyst Ratings